Maryland-based Novavax, Inc. today announced it signed agreements with its partner, SK bioscience, to manufacture and supply a version of the protein-based Novavax COVID-19 vaccine containing the Omicron variant.
The companies signed an agreement for the technology transfer of Novavax's proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants, including the Omicron BA.5 subvariant.
"Non-clinical data generated to date demonstrate that our COVID-19 vaccine offers broad immune responses including against circulating variants, such as Omicron BA.5," said Stanley C. Erck, President and Chief Executive Officer, Novavax, in a related press release issued on July 19, 2022.
"We are accelerating our clinical program evaluating an Omicron BA.5 component to our vaccine and look forward to continuing to work with SK bioscience as an important manufacturing partner."
In addition, the companies have signed an agreement to manufacture and supply the Novavax COVID-19 vaccine in a prefilled syringe.
SK bioscience will begin work to enable the manufacturing process for commercial supply of the vaccine in prefilled syringes in 2023.
Novavax and SK bioscience also have a collaboration and licensing agreement under which SK bioscience exclusively commercializes the Novavax COVID-19 vaccine in South Korea, and with Novavax jointly commercializes the vaccine in Vietnam and Thailand.
Known as Nuvaxovid™ and CovoVax™ internationally, Novavax's vaccine is authorized in over 40 countries.
In the USA, the Novavax COVID-19 Vaccine, Adjuvanted, is authorized under a U.S. FDA Emergency Use Authorization to provide a two-dose primary series for active immunization to prevent COVID-19 caused by the SARS-CoV-2 virus in individuals 18 years of age and older.
Note: The company's press release was curated for mobile readers.